Sales of Legal Cannabis and CBD Products are Projected to Grow

NEW YORK, January 31, 2018 /PRNewswire/ --

According to Hexa Research, the U.S. medical cannabis market was valued at USD 5.44 billion in 2016 and is expected to be valued at USD 19.48 billion by 2024. Numerous medical benefits of cannabis deal with cancer, chronic pain, and diabetes are important factors that drive the market. A Major segment of the legal cannabis industry is the hemp-derived cannabidiol (CBD) market. According to a report by Forbes, Brightfield Group estimates that CBD sales have already hit $170 million in 2016 and at a 55% compound annual growth rate over the next five years the market will cross the billion-dollar mark. Chineseinvestors.com, Inc. (OTC: CIIX), PotNetwork Holding, Inc. (OTC: POTN), Medical Marijuana, Inc. (OTC: MJNA), Cannabis Sativa, Inc. (OTC: CBDS), CV Sciences, Inc. (OTC: CVSI)

"One of the most surprising things we found during this research was how many companies are currently operating in the space, and how few of them are generating significant revenue," said Bethany Gomez, the Director of Research at Brightfield Group. "Essentially everyone is trying to do hemp, but only a handful are doing it well. It's seen as easy because it can be sold online but, with restrictions on traditional marketing, it is very difficult to connect with your core consumer and even communicate why they need your product," Forbes reported.

Chineseinvestors.com, Inc. (OTCQB: CIIX) last week announced breaking news that its, "mission is to become the leading publicly traded company targeting Chinese medicinal marijuana." Offering a variety of investor education products and services, Warren Wang, CEO and founder, would like to see 2018 bring with it double the revenue and expanded business. One of the ways CIIX is tackling this goal is through a Yelp-style app. Approved for download by the Apple App Store, this is the world's first Chinese-language mobile cannabis navigation application. Within the app is a database of marijuana dispensaries and cannabis strains. The platform allows for review and discussion on cannabis products, allowing customers to find the best recommendations and nearby locations for medical and recreational cannabis.

CIIX is committed to the continual study of cannabidiol (CBD) oil to treat epilepsy and Alzheimer's disease. It is the company's goal, through the use of CBD oil, to be the first enterprise in China to decrease the suffering of epilepsy and Alzheimer patients. While the U.S. sometimes treats epilepsy through high risk surgical treatments, there is no similar practice in China. With nearly 10 million epilepsy patients, CIIX is focused on forward movement toward a cure, and its management team believes that CBD may hold the answer.

The company's hemp-based health products are available in the U.S. and Canada, with promise of expansion. Marijuana use in China is illegal, but cannabis-based oils, including hemp-based CBDs, are legal. CIIX is committed to developing and distributing hemp-based products in hopes of helping people improve their overall health. It is targeting epilepsy, Alzheimer's disease, cirrhosis of the liver and various other health conditions. In January 2017, the company launched http://www.ChineseCBDoil.com, which continues to provide nutritional supplements containing CBD. The company is looking forward to the opening of a retail store in San Gabriel, California's predominantly Chinese community in the coming months."

PotNetwork Holding, Inc. (OTC: POTN) is a publicly traded company that acts as a holding company for its subsidiaries, First Capital Venture Co., the owner of Diamond CBD, Inc., the maker of Diamond CBD oils. Recently, the company announced that as a result of the rapid growth in sales of its wholly owned subsidiary, Diamond CBD, Inc., it had achieved approximately $14.5 Million in revenues for calendar 2017. Earlier Company projection had been for $8.3 Million, which were exceeded by over 70%, due to rapid month-over-month growth in sales. Diamond CBD focuses on the research, development, and multi-national marketing of premium hemp extracts that contain a broad range of cannabinoids and natural hemp derivatives. Diamond CBD's team consists of hemp industry pioneers and natural product experts, chemists, doctors and scientists, dedicated to producing the finest and purest cannabidiol (CBD) oils. The result is a robust selection considered among the most powerful natural CBD oils, tinctures, edibles, and vape liquids found anywhere.

Medical Marijuana, Inc. (OTC: MJNA) is the first-ever publicly traded cannabis company in the United States. On January 30, 2018, the company announced that it has been named one of three top hemp producers of 2018 by MMJ Reporter. Medical Marijuana, Inc. has become one of the most respected and recognized leaders in the CBD hemp oil market because of its flagship product Real Scientific Hemp Oil™ (RSHO™), which is now being subsidized by the Brazilian government and exported into several other Latin American countries such as Mexico and even as a medicine in Paraguay. In 2017, the Company experienced year-over-year growth of more than 300% compared to 2016. In 2018, Medical Marijuana, Inc. will be excited to announce many new CBD hemp oil products under its subsidiaries Kannaway®, HempMeds® and Phyto Animal Health and help promote access to CBD hemp oil across the globe.

Cannabis Sativa, Inc. (OTCQB: CBDS) is engaged in the licensing of cannabis related intellectual property, marketing and branding for cannabis based products and services, operation of cannabis related technology services, and ancillary business activities. CBDS licenses the "hi" and "White Rabbit" brands, holds a U.S. patent on the Ecuadorian Sativa strain of Cannabis, owns patent pending and trade secret formulas and processes, offers the hi benefits discount pharmacy card, and operates subsidiaries including: PrestoDoctor, Wild Earth Naturals, and iBudtender. In addition, CBDS seeks strategic partners for acquisition of operating companies, intellectual property and other assets which fit within the CBDS corporate vision. On December 4, 2017, the company announced that its subsidiary, PrestoDoctor, is expanding its online medical marijuana recommendation services into New York. PrestoDoctor currently serves patients via both their online platform and with dispensary kiosks operating in California and Nevada and will now extend their online services to patients located in the State of New York.

CV Sciences, Inc. (OTCQB: CVSI) operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD; and a consumer product division in manufacturing, marketing and selling plant-based CBD products to a range of market sectors. Recently, the company announced that it will be exhibiting its industry-dominating brand of hemp-derived CBD oil finished products, PlusCBD Oil™, at the 2018 Integrative Health Symposium, held on February 22-24, 2018 at the New York Hilton Midtown, NY in New York, New York. This will be the Company's second year exhibiting at this cutting-edge integrative practitioner conference.

Subscribe Now! Watch us report from LIVE https://www.youtube.com/FinancialBuzzMedia

Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz

Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz

Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/

About FinancialBuzz.com

FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the 'Site') is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For chineseinvestors.com Inc. financial news dissemination and PR services, FinancialBuzz.com expects to be compensated three thousand dollars by the company. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com has signed a two year agreement with Chineseinvestors.com Inc. for one hundred thousand restricted common shares for continued financial news dissemination and PR services. FinancialBuzz.com does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: http://www.financialbuzz.com.

Media Contact:
[email protected]
+1-877-601-1879

Url: http://www.FinancialBuzz.com

SOURCE FinancialBuzz.com